Skip to main content

Want a detailed portfolio tracker?

Performance analysis of Context Therapeutics (CNTX)

Annual Return

Over the past 3 years, CNTX has had an average annual return of +23.70%, outperforming the benchmark SPY, which returned +22.77% annual.

Since Oct 20, 2021, CNTX has had an average annual return of -14.90%, underperforming the benchmark SPY, which returned +13.38% annual.

202620252024202320222021
+64.64%+39.97%-7.08%+73.40%-75.50%-47.84%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026+77.59%-13.79%+16.43%-9.93%+20.77%-15.09%+64.64%
2025-13.02%-2.85%-31.03%+41.67%-33.41%+13.52%+11.36%+15.09%+15.36%+12.47%+2.76%+31.24%+39.97%
2024-9.75%+11.75%+21.07%-2.59%+47.27%+1.26%+7.73%+13.91%-20.34%+11.24%-30.29%-30.91%-7.08%
2023+62.60%-27.33%-27.02%+3.36%+49.78%+83.88%-31.24%-6.35%+46.58%-29.82%-19.78%+32.93%+73.40%
2022-23.31%-7.85%+15.44%-33.18%+54.48%-5.35%-10.85%+0.51%-41.58%+13.56%+9.51%-52.77%-75.50%
2021+12.94%+19.44%-61.33%-47.84%

Drawdown analysis of Context Therapeutics (CNTX)

The maximum drawdown for the CNTX was -93.53%, occurring on May 4, 2023. This drawdown has not yet recovered.

The current CNTX drawdown is -67.52%.

Since Oct 20, 2021 CNTX has experienced the following drawdowns:

  • 50% or more: 1 time
  • 40% or more: 1 time
  • 30% or more: 1 time
  • 20% or more: 1 time
  • 10% or more: 1 time
DepthStartTo BottomBottomTo RecoverEndTotal
-93.53%Oct 25, 2021383May 4, 2023OngoingOngoingOngoing